Introducing Spikevax XBB.1.5 from Moderna
COVID-19 isn’t giving up – and neither are we.1,2Especially for your at-risk patients.1,2 The Omicron subvariant XBB.1.5 has shown to be more transmissible than some…
Promoted
As we transition out of the pandemic and COVID statistics no longer lead the news, your patients are quickly forgetting about the risks that the virus…
Beyond GLP-1 RAs: Boosting glycaemic control for patients with T2D
While GLP-1 RAs are the usual first injectable therapy for T2D in Australia, many patients will need further intensification with treatment such as insulin, especially…
Choosing an Antidepressant – Whose Decision Is It?
Adherence to medication treatment is a growing issue, with up to 60% of patients discontinuing antidepressant treatment within 3 months.1 Adherence to antidepressants is crucial…
Why a 4th-generation topical retinoid treatment delivers quick and lasting results for acne patients
This article was written by AusDoc’s commercial team for Galderma Acne vulgaris is a chronic, multifactorial inflammatory disease and may have profound negative emotional and…
Vaping enforcement is coming. Is your practice prepared?
Mark Butler, Minister for Health, has announced that a ban on the importation of disposable vapes will commence on 1 January 2024. In parallel with…
Prescribing guidance for therapeutic nicotine vaping products (NVPs)
Becoming an Authorised Prescriber (AP) is only the first step in successfully prescribing NVPs to your patients. In order to streamline the prescribing process, Liber…
Australia’s BP control rate: less than the best
This content is produced and promoted by Servier A National Hypertension Taskforce has been established to improve Australia’s BP control rate from32% to 70% by…
How do we balance HbA1c goals and hypoglycaemia risk?
1 in 2 people with T2DM are not at target HbA1c1 Real-world and RCT evidence supports Toujeo (insulin glargine 300 U/mL) for balancing efficacy in…
Empagliflozin: a modern approach to type 2 diabetes management and CV risk reduction
Sydney endocrinologist talks about the changing treatment landscape
